Tuesday, 17 Sep 2019

You are here

High Dose Flu Vaccine for Patients Younger Than 65?

We are diving head first into flu season and we need to prepare ourselves. Last year we now know that 80,000 Americans died from influenza. I was happy to see the abstract presented in today’s plenary session by Colmegna et al about efficacy of high dose influenza vaccine in patients with rheumatoid arthritis (#837). This study was a randomized, modified double-blind, active-controlled trial carried out in adults with RA. They assessed antibody responses to standard dose quadrivalent influenza vaccine versus high-dose (trivalent).

This was a single center study and patients were recruited both during the 2016-2017 and 2017-2018 flu seasons. The study design was interesting in that they stratified the subjects into groups based on the therapy they were receiving for RA three months prior to enrollment: Group 1 = anti-cytokine, Group 2 = anti-B-cell therapy, and Group 3 = small molecules.

Seroconversion and seroprotection were assessed at day 0 and 28 days post-vaccine with serum hemagglutination inhibition titers. The mean age was 61 years and the majority of patients were female. 140 patients received the standard dose and 139 received high dose. Overall responses were higher in the high dose group compared to the standard dose, both for seroconversion and seroprotection. The therapy-based group did not predict vaccine seroresponse.


At present time, the high-dose flu shot is recommended only for patients age 65 or older and it will be interesting to see if this study changes practice patterns, and whether or not the vaccine will be covered when given to patients younger than 65. Regardless, flu season is here to stay and please ensure all your patients are vaccinated against the flu – assess for vaccine status on every patient at every visit!

Add new comment

More Like This

Two vs. Four Weeks of Antibiotic Therapy in Septic Arthritis

A prospective trial has shown that 2 weeks of antibiotic therapy is as effective as 4 weeks of antibiotic therapy, with similar outcomes but shorter hospital stays.

This Swiss study was a prospective, unblinded, randomised, non-inferiority study comparing either 2 or 4 weeks of antibiotic therapy after surgical drainage of native joint bacterial arthritis in adults. 

Bimekizumab Add-on Therapy in Rheumatoid Arthritis

Bimekizumab is a dual inhibitor of IL-17A and IL-17F that has been shown to be effective in psoriasis and psoriatic arthritis. A proof-of-concept study shows that giving bimekizumab to rheumatoid arthritis patients not adequately controlled by certolizumab pegol resulted in a rapid decrease in disease activity achieved after 12 weeks of treatment. These findings are novel as anti-IL-17 monoclonal antibody therapy has previously been shown to be ineffective in RA.

74 Percent of Rheumatoid Arthritis Patients Dissatisfied with Treatment

CreakyJoints has completed a 258 patient survey showing that nearly three-fourths of people with rheumatoid arthritis (RA) have expressed dissatisfaction with their treatments, including conventional (csDMARDs) and biologic Disease Modifying Antirheumatic Drugs (bDMARDs).

RA Women are Less Likely to Breastfeed

A large pregnancy registry has published their results showing rheumatoid arthritis (RA) patients who become pregnant are less likely to breastfeed compared to non-RA women from the general population, with many women stopping breastfeeding so that they could start medication, even though many of these meds are safe to use during lactation.

Respiratory Risks Not Increased in RA Patients with COPD

An insurance claims based study of RA patients with COPD shows that biologics do not have an increased rate of respiratory events compared to those on conventional DMARDs. A real world cohort of RA patients with COPD was drawn from US-based MarketScan databases. Patients on biologic DMARDs and/or targeted synthetic DMARDs (tsDMARDs) were propensity matched to those on conventional synthetic DMARDs (csDMARDs).